ShEEP Request for Vevo 3100 Imaging System

医学超声技术被广泛应用于临床前研究。这些非侵入性的 对于研究人员来说，成像方式对于观察器官/组织结构、大小和 疾病阶段的血液流动以及对药物干预的反应。 所要求的设备是超高频超声波机(Vevo3100，Fujifilm， 视音学)专门为小鼠、大鼠和兔子制作的图像。 Vevo 3100系统将配备线性相控阵超声探头，专门用于 兔子大小的动物，这是我们现有设备目前无法提供的。这个 Vevo 3100系统还在超声技术上进行了几次升级，包括：1)改进 分辨率，2)减少伪影，3)实时图像处理，4)左心室跟踪，5)改进 用于快速数据采集的工作流程，6)斑点跟踪分析(用于应变分析)，7)成像 配备有注射装置(用于回声引导组织注射)的站，以及8)高通量 分析。所有这些功能将使该系统成为我们生产目标的必要部分 以及时、经济高效的方式获得高质量的数据。此外，Vevo 3100系统具有高- 分辨率超声能很好地显示肾脏，因此在肾脏病方面有应用价值。 组织，量化和分析肾脏大小的技术，以及测量血流量的能力 遍及整个骨盆区域。 这种新型Vevo 3100的功能将使我们的心血管研究小组(Roth博士， Patel、Dillmann、Hammond、Ross和Mahata)以及我们在肾脏科的同事 系(Sharma、Singh和Rajasekaran博士)有机会扩大他们的实验 能力。

Medical ultrasound techniques are widely used for pre-clinical investigations. These non-invasive imaging modalities are crucial for researchers to observe changes in organ/tissue structure, size, and blood flow during disease stages as well as in response to pharmacological interventions. The requested equipment is an ultra high-frequency ultrasound machine (Vevo3100, FUJIFILM, VisualSonics) specifically manufactured to image mice, rats, and rabbits. The Vevo 3100 system will be equipped with a linear phased array ultrasound probe specific for animals in the size range of rabbits that is not currently available on our existing equipment. The Vevo 3100 system also has several upgrades in the ultrasound technology including; 1) improved resolution, 2) reduced artifact, 3) real time image processing, 4) left ventricular tracing, 5) improved workflow for rapid data acquisition, 6) speckle tracking analysis (for strain analysis), 7) an imaging station equipped with injection mount (for echo guided tissue injections), and 8) a high throughput analysis. All these functionalities would make this system a necessary part of our goal to produce high quality data in a time and cost efficient manner. Additionally, the Vevo 3100 system with high- resolution ultrasound has applications in nephrology by providing excellent delineation of renal tissues, the technology to quantify and analyze kidney size, and the ability to measure blood flow throughout the pelvic region. The functionality of this novel Vevo 3100 will allow our cardiovascular research groups (Drs. Roth, Patel, Dillmann, Hammond, Ross, and Mahata) as well as our colleagues in the nephrology department (Drs. Sharma, Singh, and Rajasekaran) the opportunities to expand their experimental capabilities.